Ahlcon Parenterals (India) Ltd


BSE: 524448 | NSE: NA | ISIN: INE027C01011 
Market Cap: [Rs.Cr.] 248 | Face Value: [Rs.] 10
Industry: Pharmaceuticals - Indian - Formulations

 Discuss this stock

Board Meet

14-May-13 
Audited Results Ahlcon Parenterals (India) Ltd has informed BSE that the Board of Directors of the Company at its meeting held on May 14, 2013, inter alia, has considered and approved the following: 1. The Board has not considered any dividend on equity shares of the Company for the year 2012-13. 2. The Board has considered for payment of final dividend only on the Preference Shares amounting to Rs. 5,40,000/- (excluding tax on dividend) for the year 2012-13. 3. The Board has considered the proposal for the 6th Expansion Project 2013. (As per BSE Announcement Dated on 14.05.2013) 
08-Feb-13 
Quarterly Results 
09-Nov-12 
Quarterly Results (Revised) (As Per Bulletin Dated On 09.11.2012) Ahlcon Parenterals (India) Ltd has informed BSE that the resignation of Prof G. P. Talwar, independent director has been accepted by the Board and taken on records at its meeting held on November 09, 2012. (As per BSE Announcement Dated on 12.11.2012) 
28-Sep-12 
Ahlcon Parenterals (India) Ltd has informed BSE regarding Outcome of Board Meeting held on September 28, 2012. Ahlcon Parenterals (India) Ltd has informed BSE that the Board of Directors of the Company at its meeting held on September 28,2012,inter alia, have approved the following: 1. To consider and approved the transfer of 54,00,112 equity shares of Rs.10 each aggregating to 75% of the paid up share capital of the Company out of which 15,80,811 equity shares of Rs.10 each aggregating to 21.96% of the paid up share capital of the Company have been transferred from public shareholders to B.Braun Singapore PTE. Ltd under the Open Offer made by B. Braun Singapore PTE.Ltd under the SEBI (Substantial Acquisition of Shares and Takeovers)Regulations,2011 and 38,19,301 equity shares of Rs.10 each aggregating to 53.04% of the paid up share capital of the Company have been transferred from Mr.Bikramjit Ahluwalia and persons acting in concert with him to B.Braun Singapore PTE.Ltd and to record the relevant Forms FC-TRS,the above transfers being in accordance with the applicable provisions of Foreign Exchange Management Act, 1999 and the FIPB approval letter dated September 14,2012 and the applicable securities laws ; 2. Appointment of Mr.Arand Apte,Mr.Arun Mudgal and Mr.Manfred Mahrle nominated by B.Braun Singapore PTE Ltd as additional directors on the Board of the Company. 3. To take a note of the resignations of Mr. Bikramjit Ahluwalia,Chairman,D.Rohini Ahluwalia, Whole Time Director,Mr.Sudarshan Walia and Mr. S.K.Sachdeva as directors on the Board of the Company was approved. 4. To Appointment Mr.Arand Apte as the Chairman of the Company was approved. 5.To Appointment Mr. Arun Mudgal as the Managing Director of the Company was approved. 6. By virtue of the above change,the Board further reconstitution of Audit Committee and the Shareholders'/ Investors' Grievance Committee was approved. (As Per Bulletin Dated on 03.10.2012) With reference to the earlier announcement dated October 01, 2012 regarding Outcome of Board Meeting, Ahlcon Parenterals (India) Ltd has now informed BSE that the Board of Directors of the Company at its meeting held on September 28, 2012 has also took on record the change in control of the Company from the erstwhile promoters to B. Braun Singapore PTE Ltd. This is consequential to the transfer of shares approved by board of directors as mentioned in point no. 1 of the enclosed letter dated October 01, 2012. (As Per BSE Announcement Dated on 03.10.2012) 
08-Aug-12 
Quarterly Results 

AGM

27-Sep-12
Ahlcon Parenterals (India) Ltd has informed BSE regarding the details of Voting results at the 20th Annual General Meeting of the Company held on September 27, 2012, under Clause 35A. Ahlcon Parenterals (India) Ltd has submitted to BSE a copy of proceedings of the 20th Annual General Meeting (AGM) of the Company was held on September 27, 2012. (As per BSE Announcement Dated on 17.10.2012)  
30-Sep-11
AGM 30/09/2011 Ahlcon Parenterals (India) Ltd has informed BSE that the 19th Annual General Meeting (AGM) of the Company will be held on September 30, 2011, at 03.00 P.M., at the Ahlcon Public School, Mayur Vihar, Phase-I, New Delhi- 110091. (As Per BSE Announcement Website dated on 20.09.2011) Ahlcon Parenterals (India) Ltd has informed BSE that the members at the 19th Annual General Meeting (AGM) of the Company held on September 30, 2011, inter alia, have approved the following: 1. The Audited Balance Sheet of the Company as at March 31, 2011, Profit & Loss Account and Cash Flow statement for the year ended on that date together with Reports of the Board of Directors and the Auditors thereon were duly considered and approved. 2. Final Dividend of 15% (Rs. 1.5 per equity share) was declared on Equity Shares of the Company, having face value of Rs. 10 each. 3. Dr. Rohini Ahluwalia, Ms. Sudarshan Walia and Mr. S. K. Sachdeva, retiring directors of the company, were reappointed. 4. Re-appointment of M/s. Arun K. Gupta & Associates, Chartered Accountants, as Statutory Auditors of the Company to hold office until the conclusion of the next Annual General Meeting of the Company, on agreed remuneration, terms & conditions. (As Per BSE Announcement Website Dated on 01/10/2011) Ahlcon Parenterals (India) Ltd has submitted to BSE a copy of the proceedings of the 19th Annual General Meeting (AGM) of the Company held on September 30, 2011. (As Per BSE Announcement Dated on 28.10.2011) 
17-Sep-10
AGM 17/09/2010 Ahlcon Parenterals (India) Ltd has informed BSE that the members at the 18th Annual General Meeting (AGM) of the Company held on September 17, 2010, inter alia, have approved to the followings: 1. The Audited Balance Sheet of the Company as at March 31, 2010, Profit & Loss Account and Cash Flow statement for the year ended on that date together with Reports of the Board of Directors and the Auditors thereon were duly considered and approved. 2. Final Dividend of 15% was declared on Equity Shares of the Company, having face value of Rs. 10/- each. 3. Dr. S. S. Arora, Dr. S. C. L. Gupta, and Mr. Bikramjit Ahluwalia, retiring directors of the company, were reappointed. 4. Re-appointment of M/s. Arun K. Gupta Associates, Chartered Accountants, as Statutory Auditors of the Company to hold office until the conclusion of the next Annual General Meeting of the Company, on agreed remuneration, terms & conditions. 5. Increase in Remunerationof Whole Time Director, Executive Vice Chairperson & CEO, Dr. Rohini Ahluwalia, was approved. (As Per BSE Announcement Website dated on 22.09.2010) 
30-Sep-09
Ahlcon Parenterals India Ltd has informed BSE that the members at the 17th Annual General Meeting (AGM) of the Company held on September 30, 2009, inter alia, have accorded to the following: 1. Adoption of the Audited Balance Sheet of the Company as at March 31, 2009, and Profit & Loss Account for the year ended on that date together with Reports of the Board of Directors and the Auditors thereon. 2. Final dividend of 15% was declared on Equity shares of the Company having a face value of Rs 10 each. 3. Mrs. Sudarshan Walia, Mr. Arun Kumar Gupta and Prof. G P Talwar, retiring directors of the Company were reappointed. 4. Re-appointment of M/s. Arun K Gupta & Associates, Chartered Accountants, as Statutory Auditors of the Company to hold office until the conclusion of the next Annual General Meeting of the Company, on remuneration, terms & conditions. 5. Appointment of MR. S K Sachdeva, as a Director of the Company. 6. Reappointment of Dr. Rohini Ahluwalia, Executive Vice Chairperson, and Whole Time Director of the Company. Ahlcon Parenterals India Ltd has submitted to BSE a copy of the proceedings of the Annual General Meeting (AGM) of the Company held on September 30, 2009. (As Per BSE Announcement Website dated on 20.10.2009) 
30-Sep-08
Ahlcon Parenterals India Ltd has informed BSE that the members at the 16th Annual General Meeting (AGM) of the Company held on September 30, 2008, inter alia, have accorded to the following: 1. Adoption of the Audited Balance Sheet of the Company as at March 31, 2008, and Profit & Loss Account for the year ended on that date together with Reports of the Board of Directors and the Auditors thereon. 2. Final dividend of 15% was declared on Equity shares of the Company having a face value of Rs 10 each. 3. Dr. Rohini Ahluwalia, Dr. S C L Gupta and Mr. Bikramjit Ahluwalia, retiring directors of the Company were reappointed. 4. Re-appointment of M/s. Arun K Gupta & Associates, Chartered Accountants, as Statutory Auditors of the Company to hold office until the conclusion of the next Annual General Meeting of the Company, on remuneration, terms & conditions. 5. Approved the Increase of Remuneration of Dr. Rohini Ahluwalia, Executive Vice Chairperson, and Whole Time Director of the Company. 

EGM

No EGM Data Found!

Peer Comparison

Company Market Cap
(Rs. in Cr.)
P/E (TTM)
(x)
P/BV (TTM)
(x)
EV/EBIDTA
(x)
ROE
(%)
ROCE
(%)
D/E
(x)
Ajanta Pharma 2,197.50 21.73 6.17 5.40 27.3 24.2 0.72
Plethico Pharma. 688.21 59.76 1.26 33.34 -5.5 3.8 1.08
Sharon Bio-Med. 364.00 7.06 1.99 9.58 19.1 14.1 1.85
Bliss GVS Pharma 327.34 5.58 1.56 2.15 28.0 42.7 0.04
Venus Remedies 321.36 5.62 0.83 3.54 17.7 16.9 0.72
Parenteral Drugs 280.56 0.00 1.11 58.93 -16.1 -0.7 0.86
Syncom Formul. 274.96 79.04 3.29 13.86 4.3 6.7 0.09
Kappac Pharma 250.89 0.00 10.46 0.00 0.0 0.0 0.06
Ahlcon Parent(I) 248.40 19.30 4.59 22.59 12.6 17.0 0.59
Amrutanjan Healt 199.44 16.97 2.00 9.89 12.6 16.3 0.23
Arvind Remedies 161.09 3.97 1.19 6.60 15.1 16.1 2.12
Zenotech Lab. 109.83 0.00 2.13 0.00 0.0 0.0 0.08
Caplin Point Lab 99.12 6.38 3.27 1.38 29.3 33.1 0.30
Combat Drugs 95.20 0.00 16.46 0.00 0.3 0.3 0.07
Hester Bios 91.53 11.26 1.52 4.56 14.4 20.6 0.35

Futures & Options Quote

 
Expiry Date
NA
Instrument: NA
Expiry Date: NA
Strike Price: NA
Open Price: NA
Average Price: NA
No. of Contracts Traded: NA
Open Interest: NA
Underlying: NA
Option Type: NA
Market Lot: NA
Previous Close: NA
Day’s High | Low: NA | NA
Turnover (Cr.): NA
Open Int. Change: NA | NA
View detailed F& O quotes >>

Key Information

Key Executives:

Arun Kumar Gupta , Director 

S S Arora , Director 

S C L Gupta , Director 

Ranjan Kumar Sahu , Company Secretary 


Company Head Office / Quarters:
201-205 2nd Flr of ND Mall-1,
Plot 2-4 Netaji Subhash Place,
Delhi,
Delhi-110034
Phone : 91-11-42344234/42344218
Fax : 91-11-42344221
E-mail : cssahu@ahlconindia.com
Web : http://www.ahlconindia.com
Registrars:
Mas Services Limited
T-34 2nd Floor
Okhla Industrial Are
Phase II
New Delhi - 110020

Fund Holding

 
Scheme Name No. of Shares
No data found

Calendar

May-2013
M T W T F S S
20 21 22 23 24 25 26
IPO
listIssue Open : Just Dial
listIssue Closing : Onesource Techm.
Economic Events
list Adjusted Merchandise Trade Balance (Yen)
list Merchandise Trade Balance Total (Yen)
Results
list Tech Mahindra